| Multiple Sclerosis |
1 |
1 |
| Disability |
0 |
0.64 |
| Immunoglobulin G (IgG) Serum |
0 |
0.34 |
| Clinical Research |
0 |
0.32 |
| Immunoglobulin G (IgG) |
0 |
0.32 |
| Progressive Multifocal Leukoencephalopathy |
0 |
0.23 |
| Adverse Effects |
0 |
0.16 |
| Disease-Modifying Therapy |
0 |
0.99 |
| France |
0 |
0.16 |
| Glatiramer Acetate |
0 |
0.16 |
| Hand |
0 |
0.16 |
| Illinois |
0 |
0.16 |
| Interferon Beta |
0 |
0.16 |
| Leukoencephalopathy |
0 |
0.16 |
| Match |
0 |
0.16 |
| Meta-Analysis |
0 |
0.16 |
| Multiple Sclerosis Relapse |
0 |
0.16 |
| New York |
0 |
0.16 |
| Pandemic |
0 |
0.16 |
| Biologic Therapy |
0 |
0.13 |
| Healthcare and Medical Technology |
0 |
0.13 |
| COVID-19 |
0 |
0.06 |
| Medical Life |
0 |
0.06 |
| Patient Safety |
0 |
0.06 |